TimesSquare Capital Management’s NovoCure NVCR Stock Holding History

TimesSquare Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60,700	Closed	-$8.02M	–	240
2021 Q1	$8.02M	Sell	60,700 -8,800	-13%	-$1.39M	0.07%	197
2020 Q4	$12M	Sell	69,500 -72,500	-51%	-$9.92M	0.1%	196
2020 Q3	$15.8M	Sell	142,000 -77,900	-35%	-$6.23M	0.15%	187
2020 Q2	$13M	Buy	219,900 +33,000	+18%	+$2.17M	0.12%	191
2020 Q1	$12.6M	Sell	186,900 -225,100	-55%	-$17.8M	0.15%	176
2019 Q4	$34.7M	Sell	412,000 -75,000	-15%	-$6.05M	0.31%	141
2019 Q3	$36.4M	Sell	487,000 -403,015	-45%	-$32.2M	0.32%	128
2019 Q2	$56.3M	Sell	890,015 -98,375	-10%	-$4.98M	0.43%	101
2019 Q1	$47.6M	Sell	988,390 -293,285	-23%	-$14.1M	0.37%	115
2018 Q4	$42.9M	Buy	1,281,675 +99,150	+8%	+$3.63M	0.37%	113
2018 Q3	$62M	Sell	1,182,525 -303,375	-20%	-$12.1M	0.41%	97
2018 Q2	$46.5M	Buy	+1,485,900	New	+$41.3M	0.31%	128

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TimesSquare Capital Management's NVCR Position: Q2 2021 in Review

TimesSquare Capital Management sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 60,700 shares — an estimated $8.02M sold.

TimesSquare Capital Management first reported a position in NVCR in Q2 2018 and held it in 12 quarters. The position peaked at $62M in Q3 2018. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

TimesSquare Capital Management reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
TimesSquare Capital Management sold 60,700 NovoCure shares in Q2 2021, an estimated $8.02M.
TimesSquare Capital Management first reported a position in NovoCure in Q2 2018 and held it in 12 quarters.
TimesSquare Capital Management's NovoCure position peaked at $62M in Q3 2018.
361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on TimesSquare Capital Management's 13F filing for Q2 2021, filed 9 Aug 2021.